The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut
BACKGROUND/OBJECTIVE: Nunavut has the highest hospitalization rates for respiratory syncytial virus (RSV) worldwide, with rates of 166 per 1000 live births per year <1 year of age. Palivizumab was implemented in Nunavut primarily for premature infants, or those with hemodynamically significant ca...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2014/941367 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555110829391872 |
|---|---|
| author | Anna Banerji Vladimir Panzov Michael Young Bonita E Lee Muhammad Mamdani B Louise Giles Marguerite Dennis Johanne Morel Danny Bisson Bosco A Paes Charles Hui Jim Mahony |
| author_facet | Anna Banerji Vladimir Panzov Michael Young Bonita E Lee Muhammad Mamdani B Louise Giles Marguerite Dennis Johanne Morel Danny Bisson Bosco A Paes Charles Hui Jim Mahony |
| author_sort | Anna Banerji |
| collection | DOAJ |
| description | BACKGROUND/OBJECTIVE: Nunavut has the highest hospitalization rates for respiratory syncytial virus (RSV) worldwide, with rates of 166 per 1000 live births per year <1 year of age. Palivizumab was implemented in Nunavut primarily for premature infants, or those with hemodynamically significant cardiac or chronic lung disease; however, the effectiveness of the program is unknown. The objective of the present multisite, hospital-based surveillance study was to estimate the effectiveness of palivizumab in infants <6 months of age in Nunavut for the 2009 and 2010 RSV seasons. |
| format | Article |
| id | doaj-art-68c5697a65c54cfc9be367e8c5a1377c |
| institution | Kabale University |
| issn | 1198-2241 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-68c5697a65c54cfc9be367e8c5a1377c2025-02-03T05:49:33ZengWileyCanadian Respiratory Journal1198-22412014-01-0121318518910.1155/2014/941367The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in NunavutAnna Banerji0Vladimir Panzov1Michael Young2Bonita E Lee3Muhammad Mamdani4B Louise Giles5Marguerite Dennis6Johanne Morel7Danny Bisson8Bosco A Paes9Charles Hui10Jim Mahony11Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Ontario, CanadaLi Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Ontario, CanadaIWK Children’s Hospital, Halifax, Nova Scotia, CanadaProvincial Public Health Laboratory, Edmonton Clinic Health Academy (ECHA), Edmonton, Alberta, CanadaLi Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Ontario, CanadaWinnipeg Children’s Hospital, Winnipeg, Manitoba, CanadaSunnybrook Health Sciences Centre, Toronto, Ontario, CanadaMontreal Children’s Hospital, Montreal, Quebec, CanadaJA Hildes Northern Medical Unit, Winnipeg, Manitoba, CanadaDepartment of Pediatrics, McMaster University, Hamilton, CanadaChildren’s Hospital of Eastern Ontario, Ottawa, CanadaRegional Virology & Chlamydiology Laboratory, Department of Pathology and Molecular Medicine, McMaster University, St Joseph’s Healthcare, Hamilton, Ontario, CanadaBACKGROUND/OBJECTIVE: Nunavut has the highest hospitalization rates for respiratory syncytial virus (RSV) worldwide, with rates of 166 per 1000 live births per year <1 year of age. Palivizumab was implemented in Nunavut primarily for premature infants, or those with hemodynamically significant cardiac or chronic lung disease; however, the effectiveness of the program is unknown. The objective of the present multisite, hospital-based surveillance study was to estimate the effectiveness of palivizumab in infants <6 months of age in Nunavut for the 2009 and 2010 RSV seasons.http://dx.doi.org/10.1155/2014/941367 |
| spellingShingle | Anna Banerji Vladimir Panzov Michael Young Bonita E Lee Muhammad Mamdani B Louise Giles Marguerite Dennis Johanne Morel Danny Bisson Bosco A Paes Charles Hui Jim Mahony The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut Canadian Respiratory Journal |
| title | The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut |
| title_full | The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut |
| title_fullStr | The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut |
| title_full_unstemmed | The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut |
| title_short | The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut |
| title_sort | real life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in nunavut |
| url | http://dx.doi.org/10.1155/2014/941367 |
| work_keys_str_mv | AT annabanerji thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT vladimirpanzov thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT michaelyoung thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT bonitaelee thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT muhammadmamdani thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT blouisegiles thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT margueritedennis thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT johannemorel thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT dannybisson thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT boscoapaes thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT charleshui thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT jimmahony thereallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT annabanerji reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT vladimirpanzov reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT michaelyoung reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT bonitaelee reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT muhammadmamdani reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT blouisegiles reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT margueritedennis reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT johannemorel reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT dannybisson reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT boscoapaes reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT charleshui reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut AT jimmahony reallifeeffectivenessofpalivizumabforreducinghospitaladmissionsforrespiratorysyncytialvirusininfantsresidinginnunavut |